Online CME: Parkinson's Disease
The Future of Parkinson’s Disease: Diagnosis and Management
Credits: 1.00
Fee: None
Expires: Not Listed
Multimedia: None
Complete this program to review neuroprotective treatment strategies for Parkinson’s disease, the neuroprotective effects of dopaminergic therapies that are currently available, emerging therapies for treating both motor and non-motor symptoms of Parkinson’s disease, drug delivery advances, the “unmet need for valid rating scales to identify early nonmotor symptoms of PD,” and potential biomarkers for aiding in early Parkinson’s disease diagnosis.
Click here to access this third-party resource
Strategies for Parkinson’s Disease Care: Evolving Approaches to Initial and Combination Therapy with Monoamine Oxidase Inhibitors
Credits: 1.00
Fee: None
Expires: Not Listed
Multimedia: None
The mechanism of action of MAO-B inhibitors and why these agents are a good choice for initial monotherapy in patients with Parkinson’s disease; their role as adjunct therapy with levodopa in patients with advanced disease who experience motor fluctuations and dyskinesia; the differences in efficacy, safety, and tolerability profiles of rasagiline and selegiline; and the “potential neuroprotective effect of MAO-B inhibitors in animal models of PD” form the foci of this course.
Click here to access this third-party resource
Credits: 1.00
Fee: None
Expires: Not Listed
Multimedia: None
Complete this program to review neuroprotective treatment strategies for Parkinson’s disease, the neuroprotective effects of dopaminergic therapies that are currently available, emerging therapies for treating both motor and non-motor symptoms of Parkinson’s disease, drug delivery advances, the “unmet need for valid rating scales to identify early nonmotor symptoms of PD,” and potential biomarkers for aiding in early Parkinson’s disease diagnosis.
Click here to access this third-party resource
Strategies for Parkinson’s Disease Care: Evolving Approaches to Initial and Combination Therapy with Monoamine Oxidase Inhibitors
Credits: 1.00
Fee: None
Expires: Not Listed
Multimedia: None
The mechanism of action of MAO-B inhibitors and why these agents are a good choice for initial monotherapy in patients with Parkinson’s disease; their role as adjunct therapy with levodopa in patients with advanced disease who experience motor fluctuations and dyskinesia; the differences in efficacy, safety, and tolerability profiles of rasagiline and selegiline; and the “potential neuroprotective effect of MAO-B inhibitors in animal models of PD” form the foci of this course.
Click here to access this third-party resource
Comment(s)
Your comments are valuable to us. Thank you.
Sorry, you must be logged in and registered to post a comment.
Related Articles

American Journal of Managed Care
American Journal of Pharmacy Benefits
HCPLive
ONCLive
OTCGuide
Pharmacy Times
Physician's Money Digest
American Journal of Pharmacy Benefits
HCPLive
ONCLive
OTCGuide
Pharmacy Times
Physician's Money Digest
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.

